Newsfiscal.ai
MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab
· Published
Article summary
MacroGenics reported positive interim Phase 2 data for lorigerlimab in patients with advanced clear cell gynecologic cancer (CCGC), showing a 25% objective response rate.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…